抗ニューロフィラメントL抗体の2030年までの世界市場予測：製品タイプ、用途、エンドユーザー、地域別に分析

Stratistics MRCによると、抗ニューロフィラメントL抗体の世界市場は2024年に3億1,880万米ドルを占め、2030年には6億1,258万米ドルに達すると予測され、予測期間中のCAGRは11.5％です。

抗ニューロフィラメントL（NfL）抗体は、神経細胞に広く存在する構造タンパク質であるニューロフィラメント軽鎖（NfL）に結合するように作られた特殊なタンパク質です。アルツハイマー病、多発性硬化症、筋萎縮性側索硬化症（ALS）のような神経変性疾患の調査や診断には、神経細胞の損傷を特定するための重要なバイオマーカーであるNfLを用いることが多くなっています。これらの抗体は神経疾患の早期発見とモニタリングをサポートし、診断アッセイの開発、神経細胞の完全性に関する研究、治療技術の進歩に不可欠です。

Parkinson's Foundationによると、2022年現在、米国では約100万人がパーキンソン病（PD）を患っています。

神経変性疾患の有病率の上昇

抗ニューロフィラメントL（NfL）抗体の必要性は、多発性硬化症、パーキンソン病、アルツハイマー病などの神経変性疾患の罹患率の増加が主な要因となっています。NfLは神経細胞傷害を特定するのに不可欠なバイオマーカーであり、早期診断や状態監視に役立ちます。人口の高齢化が進み、これらの疾患の有病率が世界的に上昇するにつれ、高度な診断技術がますます必要となってきています。さらに、学者やヘルスケア専門家の間でNfLバイオマーカーの重要性に関する知識が広まったことで、臨床や研究の場での利用が加速し、市場の拡大を後押ししています。

標準化された測定法の欠如

抗ニューロフィラメントL（NfL）抗体市場では、アッセイ法が標準化されていないことが大きな課題となっており、市場の成長にマイナスの影響を与えています。アッセイプロトコルのばらつきは、臨床診断や調査研究の信頼性・再現性を損なう。このため、研究者、医師、規制当局の信頼が損なわれ、より広範な採用が妨げられています。さらに、共通の標準がないため、異なる研究のデータを比較することが難しくなり、神経変性疾患に関する新たな治療法や研究の開発が遅れてしまいます。この問題を解決するためには、利害関係者が協力して、正確性、統一性、より広い利用可能性を保証する規範を作成しなければならないです。

バイオマーカー研究の進歩

バイオマーカーに関する調査が、抗神経フィラメントL（NfL）抗体市場を大きく成長させています。神経変性疾患の重要なバイオマーカーとしてNfLが同定されて以来、超高感度イムノアッセイ（Simoaなど）のような新技術により、これまで達成できなかったレベルでの検出能力が向上しています。これらの開発により、特に多発性硬化症、アルツハイマー病、ALSのような疾患の早期診断、疾患の経過の追跡、治療効果の評価が容易になった。臨床試験におけるNfLの有用性を実証した研究の進歩により、製薬企業は現在バイオマーカー研究に投資しています。

偽陽性・偽陰性の可能性

NfLは神経変性疾患に対する有望なバイオマーカーであるが、偽陽性や偽陰性の結果が出るリスクもあり、臨床上の意思決定に大きな影響を与える可能性があります。サンプルの取り扱い、保存条件、妨害物質の存在などの要因は、NfL測定の精度に影響を及ぼす可能性があります。さらに、個々のNfLレベルにはばらつきがあるため、決定的な診断閾値を設定することは困難です。偽結果のリスクを最小化するためには、アッセイプロトコルを最適化し、高品質の試薬を使用し、厳格な品質管理対策を実施することが不可欠です。

COVID-19の影響

抗ニューロフィラメントL（NfL）抗体の売上は、COVID-19の流行に大きな影響を受けています。COVID-19は神経炎症や神経変性などの神経症状と関連しているため、神経損傷の程度を判定し、病気の経過を追跡するためのバイオマーカーとしてNfLへの関心が高まっています。その結果、NfL抗体に対する需要が診断と調査の両面で高まっています。NfLに基づく診断検査の採用は、パンデミックによって遠隔ヘルスケアソリューションの開発が加速していることも影響しているかもしれないです。

予測期間中、モノクローナル抗体分野が最大となる見込み

モノクローナル抗体セグメントは、その高い特異性、感度、再現性により、さまざまな生物学的サンプル中のNfLレベルの検出と定量に理想的であるため、最大と推定されます。モノクローナル抗体は、NfLタンパク質上の特定のエピトープを標的とするように設計できるため、精密で正確な測定が可能です。さらに、モノクローナル抗体技術の進歩は、高感度で特異的なアッセイの開発につながり、市場の成長をさらに促進しています。

予測期間中、学術機関セグメントが最も高いCAGRが見込まれる

学術機関セグメントは予測期間中、最も高いCAGRが見込まれます。これらの機関では、神経変性疾患に関する広範な研究が行われており、疾患のメカニズムを理解し、潜在的な治療標的を特定するための貴重なバイオマーカーとしてNfLが利用されています。研究目的での高品質なNfL抗体の需要が市場の成長を後押ししています。さらに、製薬会社やバイオテクノロジー企業との学術的共同研究は、革新的なNfLベースの診断ツールや治療介入の開発を加速させています。

最大のシェアを占める地域

急速な高齢化、神経疾患率の上昇、医療施設の拡大により、予測期間中、アジア太平洋地域が最大の市場シェアを占めると予想されます。この地域は人口が多く、ヘルスケア支出が増加しているため、NfL検査のような高度な診断機器に対するニーズが著しく高まっています。市場の拡大は、ヘルスケアと医学研究を支援する政府プログラムの増加によっても推進されています。NfL抗体の需要は、同地域がさらに市場開拓を進めるにつれて増加すると予想され、国際企業にとって極めて重要な市場となっています。

CAGRが最も高い地域：

北米は、ヘルスケアインフラが発達し、高齢者人口が増加し、ヘルスケアの研究開発に力を入れていることから、予測期間中に最も高いCAGRを記録すると予測されます。この地域ではALSやアルツハイマーなどの神経変性疾患の発生率が増加しているため、NfLのような精密で感度の高いバイオマーカーの必要性が高まっています。さらに、NfLに基づく診断テストや治療介入の開発とマーケティングは、北米の著名な製薬会社やバイオテクノロジー企業の存在によって促進されています。

無料のカスタマイズサービス

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• ドライバー
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の抗ニューロフィラメントL抗体市場：製品タイプ別

• モノクローナル抗体
• ポリクローナル抗体
• その他の製品タイプ

第6章 世界の抗ニューロフィラメントL抗体市場：用途別

• 研究
• 診断
• 医薬品の発見と開発
• 治療薬
• その他の用途

第7章 世界の抗ニューロフィラメントL抗体市場：エンドユーザー別

• 学術機関
• 製薬・バイオテクノロジー企業
• 研究所
• その他のエンドユーザー

第8章 世界の抗ニューロフィラメントL抗体市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東・アフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイリング

• Merck KGaA
• Abcam plc
• Thermo Fisher Scientific Inc.
• Santa Cruz Biotechnology, Inc.
• Proteintech Group, Inc.
• R&D Systems, Inc.
• Boster Biological Technology
• Rockland Immunochemicals Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• GeneTex, Inc.
• Novus Biologicals, LLC
• ProSci Inc.
• Atlas Antibodies AB
• LifeSpan BioSciences, Inc.
• Creative Biolabs
• BioLegend, Inc.
• Abnova Corporation
• PeproTech, Inc.
• US Biological Life Sciences

List of Tables

• Table 1 Global Anti Neurofilament L Antibody Market Outlook, By Region (2022-2030) ($MN)
• Table 2 Global Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
• Table 3 Global Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
• Table 4 Global Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
• Table 5 Global Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
• Table 6 Global Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
• Table 7 Global Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
• Table 8 Global Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
• Table 9 Global Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
• Table 10 Global Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
• Table 11 Global Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 12 Global Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
• Table 13 Global Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
• Table 14 Global Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
• Table 15 Global Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
• Table 16 Global Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 17 North America Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
• Table 18 North America Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
• Table 19 North America Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
• Table 20 North America Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
• Table 21 North America Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
• Table 22 North America Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
• Table 23 North America Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
• Table 24 North America Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
• Table 25 North America Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
• Table 26 North America Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
• Table 27 North America Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 28 North America Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
• Table 29 North America Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
• Table 30 North America Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
• Table 31 North America Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
• Table 32 North America Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 33 Europe Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
• Table 34 Europe Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
• Table 35 Europe Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
• Table 36 Europe Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
• Table 37 Europe Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
• Table 38 Europe Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
• Table 39 Europe Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
• Table 40 Europe Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
• Table 41 Europe Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
• Table 42 Europe Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
• Table 43 Europe Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 44 Europe Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
• Table 45 Europe Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
• Table 46 Europe Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
• Table 47 Europe Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
• Table 48 Europe Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 49 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
• Table 50 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
• Table 51 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
• Table 52 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
• Table 53 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
• Table 54 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
• Table 55 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
• Table 56 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
• Table 57 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
• Table 58 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
• Table 59 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 60 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
• Table 61 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
• Table 62 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
• Table 63 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
• Table 64 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 65 South America Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
• Table 66 South America Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
• Table 67 South America Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
• Table 68 South America Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
• Table 69 South America Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
• Table 70 South America Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
• Table 71 South America Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
• Table 72 South America Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
• Table 73 South America Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
• Table 74 South America Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
• Table 75 South America Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 76 South America Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
• Table 77 South America Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
• Table 78 South America Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
• Table 79 South America Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
• Table 80 South America Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
• Table 81 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
• Table 82 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
• Table 83 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
• Table 84 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
• Table 85 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
• Table 86 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
• Table 87 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
• Table 88 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
• Table 89 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
• Table 90 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
• Table 91 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 92 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
• Table 93 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
• Table 94 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
• Table 95 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
• Table 96 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)

According to Stratistics MRC, the Global Anti Neurofilament L Antibody Market is accounted for $318.80 million in 2024 and is expected to reach $612.58 million by 2030 growing at a CAGR of 11.5% during the forecast period. Anti-neurofilament L (NfL) antibodies are specialized proteins made to attach to the neurofilament light chain (NfL), a structural protein that is widely present in neurons. Research and diagnosis of neurodegenerative illnesses like Alzheimer's, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are increasingly using NfL, a critical biomarker for identifying neuronal damage. These antibodies support early detection and monitoring of neurological diseases and are essential for the development of diagnostic assays, research into neuronal integrity, and advancement of therapeutic techniques.

According to Parkinson's Foundation, as of 2022, nearly one million people in the United States are living with Parkinson's disease (PD).

Market Dynamics:

Driver:

Rising prevalence of neurodegenerative diseases

The need for anti-neurofilament L (NfL) antibodies is mostly driven by the increasing incidence of neurodegenerative illnesses such as multiple sclerosis, Parkinson's, and Alzheimer's. NfL is an essential biomarker for identifying neuronal injury, which helps with early diagnosis and status monitoring. Advanced diagnosis technologies are becoming more and more necessary as populations age and the prevalence of these ailments rises worldwide. Furthermore, increased knowledge of the significance of NfL biomarkers among academics and healthcare professionals has accelerated their use in clinical and research settings, supporting the market's expansion.

Restraint:

Lack of standardized assay methods

The lack of standardized assay methods in the Anti-Neurofilament L (NfL) Antibody Market poses significant challenges, negatively impacting its growth. Assay protocol variability produces variable results, which compromises clinical diagnostics and research study reliability and reproducibility. This hinders wider adoption by undermining trust among academics, physicians, and regulatory agencies. Furthermore, the lack of common standards makes it more difficult to compare data from different studies, which slows down the development of new treatments and research on neurodegenerative diseases. In order to resolve this issue, stakeholders must work together to create norms that guarantee accuracy, uniformity, and wider accessibility.

Opportunity:

Advancements in biomarker research

Research on biomarkers is propelling the market for anti-neurofilament L (NfL) antibodies to rise significantly. Novel technologies such as ultrasensitive immunoassays (e.g., Simoa) have improved detection capabilities at previously unachievable levels since NfL was identified as a crucial biomarker for neurodegenerative disorders. These developments facilitate early diagnosis, tracking the course of the disease, and assessing the effectiveness of treatment, especially for diseases like multiple sclerosis, Alzheimer's, and ALS. Pharmaceutical corporations are now investing in biomarker studies as a result of research advances that have demonstrated the usefulness of NfL in clinical trials.

Threat:

Potential for false positive and negative results

While NfL is a promising biomarker for neurodegenerative diseases, there is a risk of false positive and negative results, which can significantly impact clinical decision-making. Factors such as sample handling, storage conditions, and the presence of interfering substances can influence the accuracy of NfL measurements. Additionally, variations in individual NfL levels can make it challenging to establish definitive diagnostic thresholds. To minimize the risk of false results, it is essential to optimize assay protocols, use high-quality reagents, and implement rigorous quality control measures.

Covid-19 Impact

Anti-Neurofilament L (NfL) antibody sales have been greatly influenced by the COVID-19 epidemic. Since COVID-19 has been linked to neurological symptoms like neuroinflammation and neurodegeneration, there has been more interest in NfL as a possible biomarker for determining the extent of neurological damage and tracking the course of the illness. As a result, there is now more demand for NfL antibodies for both diagnostic and research applications. The adoption of NfL-based diagnostic tests may also be influenced by the pandemic's acceleration of the development of remote healthcare solutions.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is estimated to be the largest, due to their high specificity, sensitivity, and reproducibility make them ideal for detecting and quantifying NfL levels in various biological samples. Monoclonal antibodies can be engineered to target specific epitopes on the NfL protein, enabling precise and accurate measurements. Additionally, advances in monoclonal antibody technology have led to the development of highly sensitive and specific assays, further driving the growth of the market.

The academic institutions segment is expected to have the highest CAGR during the forecast period

The academic institutions segment is anticipated to witness the highest CAGR during the forecast period. These institutions conduct extensive research on neurodegenerative diseases, utilizing NfL as a valuable biomarker to understand disease mechanisms and identify potential therapeutic targets. The demand for high-quality NfL antibodies for research purposes fuels the market's growth. Additionally, academic collaborations with pharmaceutical companies and biotechnology firms accelerate the development of innovative NfL-based diagnostic tools and therapeutic interventions.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rapidly aging population, rising neurological disease rates, and expanding medical facilities. The need for sophisticated diagnostic instruments like NfL tests has increased significantly because to the region's high population and growing healthcare expenditures. The market's expansion is also being driven by an increase in government programs to support healthcare and medical research. The demand for NfL antibodies is anticipated to increase as the region develops further, making it a crucial market for international companies.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period, because of a developed healthcare infrastructure, a growing senior population, and a strong emphasis on healthcare research and development. The increasing incidence of neurodegenerative illnesses like ALS and Alzheimer's in the area has raised the need for precise and sensitive biomarkers like NfL. Furthermore, the development and marketing of NfL-based diagnostic tests and therapeutic interventions have been expedited by the presence of prominent pharmaceutical and biotechnology firms in North America.

Key players in the market

Some of the key players profiled in the Anti Neurofilament L Antibody Market include Merck KGaA, Abcam plc, Thermo Fisher Scientific Inc., Santa Cruz Biotechnology, Inc., Proteintech Group, Inc., R&D Systems, Inc., Boster Biological Technology, Rockland Immunochemicals Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., GeneTex, Inc., Novus Biologicals, LLC, ProSci Inc., Atlas Antibodies AB, LifeSpan BioSciences, Inc., Creative Biolabs, BioLegend, Inc., Abnova Corporation, PeproTech, Inc., and US Biological Life Sciences.

Key Developments:

In October 2023, Quanterix Corporation launched a new high-sensitivity assay for measuring neurofilament light chain (NfL) levels, aimed at enhancing the early detection and monitoring of neurodegenerative diseases.

In September 2023, BioLegend introduced a new anti-neurofilament L antibody aimed at research applications, providing enhanced specificity and sensitivity for studying neurodegeneration.

In April 2023, Merck KGaA released an updated version of their anti-neurofilament L antibody, which includes improved formulations for better performance in clinical diagnostics.

Product Types Covered:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Product Types

Applications Covered:

• Research
• Diagnostics
• Drug Discovery and Development
• Therapeutics
• Other Applications

End Users Covered:

• Academic Institutions
• Pharmaceutical and Biotechnology Companies
• Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Anti Neurofilament L Antibody Market, By Product Type

• 5.1 Introduction
• 5.2 Monoclonal Antibodies
• 5.3 Polyclonal Antibodies
• 5.4 Other Product Types

6 Global Anti Neurofilament L Antibody Market, By Application

• 6.1 Introduction
• 6.2 Research
• 6.3 Diagnostics
• 6.4 Drug Discovery and Development
• 6.5 Therapeutics
• 6.6 Other Applications

7 Global Anti Neurofilament L Antibody Market, By End User

• 7.1 Introduction
• 7.2 Academic Institutions
• 7.3 Pharmaceutical and Biotechnology Companies
• 7.4 Laboratories
• 7.5 Other End Users

8 Global Anti Neurofilament L Antibody Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Merck KGaA
• 10.2 Abcam plc
• 10.3 Thermo Fisher Scientific Inc.
• 10.4 Santa Cruz Biotechnology, Inc.
• 10.5 Proteintech Group, Inc.
• 10.6 R&D Systems, Inc.
• 10.7 Boster Biological Technology
• 10.8 Rockland Immunochemicals Inc.
• 10.9 Bio-Rad Laboratories, Inc.
• 10.10 Cell Signaling Technology, Inc.
• 10.11 GeneTex, Inc.
• 10.12 Novus Biologicals, LLC
• 10.13 ProSci Inc.
• 10.14 Atlas Antibodies AB
• 10.15 LifeSpan BioSciences, Inc.
• 10.16 Creative Biolabs
• 10.17 BioLegend, Inc.
• 10.18 Abnova Corporation
• 10.19 PeproTech, Inc.
• 10.20 US Biological Life Sciences